FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2596281330> ?p ?o ?g. }

• W2596281330 endingPage "1402" @default.
• W2596281330 startingPage "1395" @default.
• W2596281330 abstract "Purpose Radiation therapy is a critical component in the care of patients with non–small-cell lung cancer (NSCLC), yet cardiac injury after treatment is a significant concern. Therefore, we wished to elucidate the incidence of cardiac events and their relationship to radiation dose to the heart. Patients and Materials Study eligibility criteria included patients with stage II to III NSCLC treated on one of four prospective radiation therapy trials at two centers from 2004 to 2013. All cardiac events were reviewed and graded per Common Terminology Criteria for Adverse Events (v4.03). The primary end point was the development of a grade ≥ 3 cardiac event. Results In all, 125 patients met eligibility criteria; median follow-up was 51 months for surviving patients. Median prescription dose was 70 Gy, 84% received concurrent chemotherapy, and 27% had pre-existing cardiac disease. Nineteen patients had a grade ≥ 3 cardiac event at a median of 11 months (interquartile range, 6 to 24 months), and 24-month cumulative incidence was 11% (95% CI, 5% to 16%). On multivariable analysis (MVA), pre-existing cardiac disease (hazard ratio [HR], 2.96; 95% CI, 1.07 to 8.21; P = .04) and mean heart dose (HR, 1.07/Gy; 95% CI, 1.02 to 1.13/Gy; P = .01) were significantly associated with grade ≥ 3 cardiac events. Analyzed as time-dependent variables on MVA analysis, both disease progression (HR, 2.15; 95% CI, 1.54 to 3.00) and grade ≥ 3 cardiac events (HR, 1.76; 95% CI, 1.04 to 2.99) were associated with decreased overall survival. However, disease progression (n = 71) was more common than grade ≥ 3 cardiac events (n = 19). Conclusion The 24-month cumulative incidence of grade ≥ 3 cardiac events exceeded 10% among patients with locally advanced NSCLC treated with definitive radiation. Pre-existing cardiac disease and higher mean heart dose were significantly associated with higher cardiac event rates. Caution should be used with cardiac dose to minimize risk of radiation-associated injury. However, cardiac risks should be balanced against tumor control, given the unfavorable prognosis associated with disease progression." @default.
• W2596281330 created "2017-03-23" @default.
• W2596281330 creator A5014527725 @default.
• W2596281330 creator A5014871240 @default.
• W2596281330 creator A5026453991 @default.
• W2596281330 creator A5034708452 @default.
• W2596281330 creator A5042756485 @default.
• W2596281330 creator A5045254828 @default.
• W2596281330 creator A5046132413 @default.
• W2596281330 creator A5060316016 @default.
• W2596281330 creator A5066306817 @default.
• W2596281330 creator A5072230357 @default.
• W2596281330 creator A5080211712 @default.
• W2596281330 creator A5086891939 @default.
• W2596281330 creator A5087107933 @default.
• W2596281330 creator A5087540334 @default.
• W2596281330 creator A5091161722 @default.
• W2596281330 date "2017-05-01" @default.
• W2596281330 modified "2023-10-17" @default.
• W2596281330 title "Cardiac Events After Radiation Therapy: Combined Analysis of Prospective Multicenter Trials for Locally Advanced Non–Small-Cell Lung Cancer" @default.
• W2596281330 cites W1824227359 @default.
• W2596281330 cites W1968899146 @default.
• W2596281330 cites W1984068275 @default.
• W2596281330 cites W1984502501 @default.
• W2596281330 cites W1987536026 @default.
• W2596281330 cites W1991925245 @default.
• W2596281330 cites W2019071303 @default.
• W2596281330 cites W2019607817 @default.
• W2596281330 cites W2024136031 @default.
• W2596281330 cites W2024765487 @default.
• W2596281330 cites W2045313863 @default.
• W2596281330 cites W2069704508 @default.
• W2596281330 cites W2083732963 @default.
• W2596281330 cites W2094310164 @default.
• W2596281330 cites W2102431888 @default.
• W2596281330 cites W2104701073 @default.
• W2596281330 cites W2117032294 @default.
• W2596281330 cites W2134201833 @default.
• W2596281330 cites W2140492419 @default.
• W2596281330 cites W2142397820 @default.
• W2596281330 cites W2152844787 @default.
• W2596281330 cites W2154375587 @default.
• W2596281330 cites W2159751658 @default.
• W2596281330 cites W2161540354 @default.
• W2596281330 cites W2167508271 @default.
• W2596281330 cites W2485866634 @default.
• W2596281330 cites W2528393079 @default.
• W2596281330 cites W2531388082 @default.
• W2596281330 cites W2548698776 @default.
• W2596281330 cites W2607031541 @default.
• W2596281330 cites W4236673002 @default.
• W2596281330 cites W4238251256 @default.
• W2596281330 doi "https://doi.org/10.1200/jco.2016.71.6142" @default.
• W2596281330 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5455464" @default.
• W2596281330 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28301264" @default.
• W2596281330 hasPublicationYear "2017" @default.
• W2596281330 type Work @default.
• W2596281330 sameAs 2596281330 @default.
• W2596281330 citedByCount "262" @default.
• W2596281330 countsByYear W25962813302017 @default.
• W2596281330 countsByYear W25962813302018 @default.
• W2596281330 countsByYear W25962813302019 @default.
• W2596281330 countsByYear W25962813302020 @default.
• W2596281330 countsByYear W25962813302021 @default.
• W2596281330 countsByYear W25962813302022 @default.
• W2596281330 countsByYear W25962813302023 @default.
• W2596281330 crossrefType "journal-article" @default.
• W2596281330 hasAuthorship W2596281330A5014527725 @default.
• W2596281330 hasAuthorship W2596281330A5014871240 @default.
• W2596281330 hasAuthorship W2596281330A5026453991 @default.
• W2596281330 hasAuthorship W2596281330A5034708452 @default.
• W2596281330 hasAuthorship W2596281330A5042756485 @default.
• W2596281330 hasAuthorship W2596281330A5045254828 @default.
• W2596281330 hasAuthorship W2596281330A5046132413 @default.
• W2596281330 hasAuthorship W2596281330A5060316016 @default.
• W2596281330 hasAuthorship W2596281330A5066306817 @default.
• W2596281330 hasAuthorship W2596281330A5072230357 @default.
• W2596281330 hasAuthorship W2596281330A5080211712 @default.
• W2596281330 hasAuthorship W2596281330A5086891939 @default.
• W2596281330 hasAuthorship W2596281330A5087107933 @default.
• W2596281330 hasAuthorship W2596281330A5087540334 @default.
• W2596281330 hasAuthorship W2596281330A5091161722 @default.
• W2596281330 hasBestOaLocation W25962813302 @default.
• W2596281330 hasConcept C119060515 @default.
• W2596281330 hasConcept C120665830 @default.
• W2596281330 hasConcept C121332964 @default.
• W2596281330 hasConcept C126322002 @default.
• W2596281330 hasConcept C164705383 @default.
• W2596281330 hasConcept C188816634 @default.
• W2596281330 hasConcept C207103383 @default.
• W2596281330 hasConcept C2776256026 @default.
• W2596281330 hasConcept C2777793932 @default.
• W2596281330 hasConcept C44249647 @default.
• W2596281330 hasConcept C509974204 @default.
• W2596281330 hasConcept C61511704 @default.
• W2596281330 hasConcept C71924100 @default.
• W2596281330 hasConceptScore W2596281330C119060515 @default.
• W2596281330 hasConceptScore W2596281330C120665830 @default.

• next